Key Solutions

Contact Info

4 Sunshine Blvd, Ormond Beach, FL 32174, USA

+ 1 (386) 265-4360

Contact Us

Follow Us

Category: News Releases

US Biocontainment Manufacturer Delivers Mobile Unit for Work on Coronavirus Vaccine

ORMOND BEACH, Fla. and LOUISVILLE, Ky., April 9, 2020 /PRNewswire/ — This week, Germfree delivered a 53-foot containment cleanroom trailer to a major US pharmaceutical company where they will work on a COVID-19 vaccine. This is the first, of what is expected to be, many mobile laboratory spaces that will be delivered to scientists and organizations working on virus and antibody testing, vaccine development, research, and deployment solutions. Germfree was quickly able to meet the need for a biocontainment unit specifically designed for COVID-19 vaccine development because the company has decades of experience providing rapidly deployable biocontainment laboratory space. Since the 1990s, the Germfree has pioneered the use of mobile containment cleanrooms for surge capacity, hospital renovations, and emergency preparedness. In recent years, the company has deployed over 60 mobile solutions like the ones needed to meet the COVID-19 crisis to public and private healthcare systems across the US, including to the National Institutes of Health (NIH), Massachusetts General Hospital, Stanford Health Care, Kaiser Permanente, UW Medicine, Yale New Haven Health, and the US Department of Veterans Affairs (VA).

This experience positions Germfree to provide what is needed today as well as solutions that can be easily tailored in the future to meet needs that have yet to be identified.

“While not endorsing any particular company or product, rapidly deployable, complete laboratories will greatly enhance the US response to testing for COVID-19.” said Paul Jensen, Ph.D., Lead for Infection Control and Biosafety at the Centers for Disease Control and Prevention (CDC), upon commenting on flexible solutions and laboratory safety.

Just as scientists and healthcare professionals have pivoted to focus efforts on reducing the lethality of COVID-19, Germfree employees and the company’s supply chains have coordinated to be ready to provide researchers and healthcare systems with what they need to fight this virus. Germfree’s well-trained workforce is incredibly versatile and has years of experience providing scientists and the healthcare industry with precisely what they need when they need it. With an Essential Critical Infrastructure Workforce designation from the Department of Homeland Security and procedures in place to protect the health of employees, Germfree remains ready to produce.

Over the years, Germfree has developed strong relationships with vendors, assuring a continuous supply chain for production. Some, such as Kentucky Trailer, a key provider of specialty mobile platforms, are prioritizing Germfree so that the company can quickly meet the needs in the field:

“We clearly understand the importance of Germfree’s mobile labs in the national response to COVID-19. Early on, we worked together to put a plan in place to prioritize critical production demands and maintain supply chain resiliency during these unprecedented circumstances,” said Tom Harper, a VP at Kentucky Trailer.

“As an essential critical infrastructure business, Kentucky Trailer and our dedicated associates are honored to assist Germfree in the fight against the COVID-19 pandemic,” added Gary A. Smith, Sr., President and CEO of Kentucky Trailer. “What we make matters, underscored by the importance in the combined effort of two great companies partnering to address this historic, must-win challenge.”

Other manufacturers have stepped up to formalize plans to provide Germfree with components:

“We put extra mechanisms in place to avert disruptions and secure the supply chain for Germfree during the pandemic,” said Tim Confer, President, Northern Air Systems, a provider of specialty cooling units for the mobile laboratories.

The U.S. Department of Health and Human Services (HHS) has designated Germfree and its employees as ‘Essential Mission Infrastructure Support’. Together, with its collaborating vendors, Germfree will continue to employ Americans to provide scientists and healthcare systems with the critical biocontainment capacity they need to save lives and win the fight against this virus. Germfree and its partners are essential to the mission of national health security.

# # #

High Containment Laboratory used for COVID-19 research. Shows interior of offsite-constructed facility built by Germfree Labs in its US factory and installed in Singapore. Duke-NUS researchers were among the first to culture the SARS-CoV-2 and begin study on COVID-19.

Ormond Beach, FL, US – April 1st, 2020 – By mid-March, the emerging pandemic sounded alarms at the highest levels and Germfree was being asked to provide biological containment laboratories – fast. Calls came in from public health labs and researchers across the globe who work to contain local outbreaks and prevent regional epidemics. Now facing a pandemic, priorities shifted, and efforts intensified as did the need for bio-containment space. The global response to COVID-19 would reveal critical deficiencies in global laboratory capacity that now require fast, flexible solutions.


“COVID-19 presents unprecedented challenges to our global laboratory infrastructure,” said Dr. Steven Jones, Associate Provost for Health Sciences at the University of Saskatchewan and co-discoverer of a vaccine for Ebola. Jones has confronted these concerns with previous coronavirus outbreaks. “Our laboratory capabilities must be agile and responsive to potential biological threats in a wide range of scenarios. In 2014, I worked with Germfree to quickly deploy one of their laboratories to the Middle East to deal with MERS, which was very similar to the current pandemic virus.”

High Containment Laboratory used for COVID-19 research. Shows exterior of offsite-constructed facility in Germfree’s US factory prior to shipment and installation in Singapore. Duke-NUS researchers were among the first to culture the SARS-CoV-2 and begin study on COVID-19.


Germfree-built facilities are in operation across the world, from resource-challenged regions to modern cities, including a high containment lab in Singapore at the forefront of COVID-19 research: “Duke-NUS was one of the first few laboratories in the world to culture the SARS-CoV-2 and since then we have been working on various aspects of the outbreak,” said Dr. Viji Vijayan, Associate Dean – Research Operations, Safety and Central Procurement at Duke-NUS.


“Building the labs that are crucial to Global Health Security – this is what we do. It is our responsibility to apply all our resources to assist with the pandemic at this time. Germfree is quickly adding factory capacity to build this essential infrastructure as well as offering expertise to industry partners who are trying to fulfill the unmet need,” said Kevin Kyle, President of Germfree. “While our mission is intact, the pandemic created a seismic shift of the landscape in which we all now operate. We quickly pivoted to focus our resources on those serving in the trenches of this terrible pandemic.”

BSL-3 Biological Containment Laboratory; Keith Landy, CEO of Germfree, Tom Frieden, Former CDC Director. The BSL-3 (Biosafety Level 3) laboratory was manufactured by Germfree Labs in their US factory and then shipped and installed in Zaria, Nigeria. This created a new method to augment lab infrastructure and support global public health security anywhere in the world. These labs serve as outposts for disease surveillance with the goal of containing emerging threats.


In the 1990’s, Germfree pioneered the manufacture of mobile and modular, high containment laboratories. Germfree has since further refined designs and developed the capability to rapidly deploy facilities to any region of the world, creating a new model for disease surveillance in remote areas. “Everything that Germfree has done over the last 20 years has prepared us to contribute solutions to this type of situation,” said Keith Landy, CEO of Germfree. “I first started working with the US Army to develop equipment and mobile facilities that could address biological threats and those have evolved into all of the platforms we now use to deliver offsite-built containment labs. Germfree has over a hundred laboratory installations and has deployed the most advanced Biosafety Level 3+ labs on the planet,” continued Landy. “These installations are designed to operate in harsh conditions and remain sustainable in remote regions of the world. I think this deep-rooted experience and expertise combined with our history of global deployments has prepared Germfree to solve some of the very complex challenges that we must confront during this pandemic and for future preparedness.”


“It is vital that we have sufficient global lab capacity for the outbreaks we’ve seen, but more importantly, for the ones we must predict,” added Dr. Steven Jones.

# # #

For full quotes and high resolution images please see out Press backgrounder.

Germfree partners with HOK to rapidly deploy US-based testing facilities to battle COVID-19.

Utilizing state of the art manufacturing processes, Germfree and HOK are bringing robust BSL-2+ laboratories to market that will enable testing at a level not previously seen possible.

Germfree and HOK COVID Testing Facility Image With People Walking Up to Receive Testing. Germfree and HOK branding visible, and there are large signs.
HOK teamed with Germfree Laboratories Inc. to design a mobile testing lab that will help large organizations meet this urgent need. These self-contained, biocontainment facilities can provide advanced, on-site capabilities for any setting.

University campuses, corporate campuses, business parks, and manufacturing facilities are provided full-time, high throughput testing capabilities via a space-efficient and convertible laboratory. These facilities, along with local governments, enable an expanding testing network to monitor disease transmission and protect communities nationwide.

Protecting Communities, Advancing Global Health

Enabling Scaled Local Testing

At a Germfree/HOK bioGO facility, it is estimated an average of 240 samples per day can be self-collected by the participants. With additional guidance from telemedicine, a test-kit is provided to participants who are assisted by limited personnel in PPE. These facilities limit the need for large quantities of individuals in PPE to collect samples on the ‘frontline’ which will soon become the institutions that scores of individuals will be returning to work or learn. Up to 80 batches can be processed at a time in under 60 minutes with high-throughput testing platforms such as Cepheid GeneCpert Express, which will be available lab options.

Process and registration information is provided on the website on outside the mobile lab. A healthcare worker will scan a QR code sent to each participant’s mobile device and provide further instruction. Following the provided procedures, each person will collect their own sample and test results will be released within 24 hours.

Return to Work, Done Right

The Germfree/HOK COVID-19 Testing Labs will offer a clear and controlled method for a ‘safer’ return to work. As companies and educational institutions attempt to come together again, rapid testing is the only way to ensure a return of infection is mitigated.

Mobile Adaptive Bioproduction Suite

New Bioproduction Platform to Meet Challenges of Biotech Startups

Germfree to Demonstrate Next Level in Flexible Biopharmaceutical Production

SAN DIEGO, CA; June 20th, 2017 — Today, Germfree will present its Mobile Adaptive Bioproduction Suite at the BIO International Convention in San Diego. This biopharmaceutical facility is highlighted by BIO 2017 as a featured tour on the exhibition floor. The unit is the first of its kind to provide configurable space for biotech R&D and small-scale bioproduction within a self-contained mobile platform.

These suites provide cGMP-compliant biomanufacturing solutions by integrating cleanrooms and biocontainment zones in a 53’ foot (16 meter) trailer. Previously, there were limited options for quickly addressing small-scale bioprocessing challenges. The Adaptive Suites deliver new options for fast, flexible and cost-effective production space that would be impractical in a brick and mortar building. Germfree’s advanced platforms are engineered to operate as stand-alone facilities and can be easily repurposed and relocated globally.

In recent years, the number of new biotechnology startups has skyrocketed. However, many small-scale pharmaceutical projects lack the viable infrastructure to meet their demands. Concurrently, there has been an industry-wide shift toward more flexible manufacturing environments. “The biotech industry is under intense pressure to adapt to production processes and facilities that keep up with the rapid pace of innovation.” said Jeff Serle, Senior VP, Germfree. “We’ve engineered the Mobile Adaptive Bioproduction Suite to provide the next level of flexibility that is key in the early stages of drug development. Germfree rapidly deploys turnkey facilities anywhere they are needed, for the duration of the project. Startups are able to begin R&D or early small-batch production without committing to traditional building construction or renovations which significantly reduces initial capital expenditures.”

The Adaptive Mobile Suites are adaptable for emerging processes and all core equipment is interchangeable. The units accommodate a wide range of scientific instrumentation, bioproduction equipment and any engineering controls for primary and secondary biocontainment. Recent innovations in high-performance, compact biotech components further promote the adaptability of the Germfree trailer. “Our mobile unit fits seamlessly at the intersection of emerging biotherapeutics, applications that require flexible space and new small-footprint bioprocessing equipment.” says Carol Houts, Director of Quality, Germfree.

Germfree’s Adaptive Bioproduction Suites are optimal for a wide range of biotechnology research, development and production applications. These include: monoclonal antibodies, therapeutic proteins, gene therapy, viral vector, cell therapy and live virus vaccines. “Our platform will help solve small-scale processing challenges especially for precision medicine.” continues Carol Houts. “The Adaptive Suite is easily configured to the ISO cleanroom grade or biosafety demands of each application. The capabilities of the mobile suite will also help facilitate the rapid development and clinical trial biomanufacturing processes that are critical to product pipeline success.”

# # #

About GERMFREE
Germfree manufactures advanced cGMP-compliant mobile and modular bioproduction and biocontainment platforms. The company was established in 1962 to provide aseptic control and biosafety for institutions ranging from hospital pharmacies to high containment laboratories. Today, Germfree’s BSL-3 labs are deployed globally to meet the rigorous demands of military and public health agencies. This extensive experience has positioned Germfree to build cleanroom platforms, which exceed the engineering standards of traditional facilities. Our leading-edge fabrication technology, engineering teams and subject-matter experts are located at our 173,000 square foot (16,000 square meter) US manufacturing plant.

The Mobile Adaptive Bioproduction Suite will be located at Booth #6247 at BIO 2017, June 20 – 22, at the San Diego Convention Center.

For media inquiries, please contact Craig Landy [email protected] +1 386-316-2799
For further information about BIO please visit: convention.bio.org

News Release

For media inquiries, please contact Craig Landy – [email protected] – 386-265-4360 or 386-316-2799

First ‘Adaptive Bioproduction Suite’ to Debut at Premier BioPharma Event

INTERPHEX to Showcase New Flexible Biopharmaceutical Production Platform

 
DAYTONA BEACH, FL; March 8th, 2017 – Germfree will introduce its Mobile Adaptive Bioproduction Suite on March 21, 2017 at International Pharmaceutical Expo (INTERPHEX), the premier event dedicated to pharmaceutical, biotechnology and device innovation, technology and knowledge from development through commercialization. This adaptive cleanroom trailer is the first of its kind to provide configurable space for cGMP production, R&D and biocontainment within a self-contained mobile platform. Accelerated innovation in the biopharmaceutical industry has generated a shift toward more flexible manufacturing environments. The Bioproduction Suite is a new approach for rapid deployment of cleanrooms and adaptable platforms for bioprocessing. INTERPHEX takes place March 21-23, 2017 at the Jacob Javits Center in New York, New York.

The 53’ (16 meter) stand-alone cGMP facility will be featured as a special event at INTERPHEX 2017. “INTERPHEX offers the ideal venue to demonstrate technologies that represent the future of pharmaceutical and biologics development and production,” said Melissa Ashley, Senior Vice President, INTERPHEX. “We are delighted that Germfree will exhibit a mobile adaptive bioproduction suite for attendees to walk through and experience solutions that maximize onsite space and offer personnel safety and containment control in a self-contained platform right on the show floor.”

Adaptive Bioproduction Suites are configured to meet the specific technical and validation requirements for each application. The units are ideally suited to adjust for emerging biopharmaceutical processes as they utilize Germfree’s interchangeable casework and laminar flow equipment. The Bioproduction Suite will be presented at INTERPHEX as a concept cleanroom facility. Specialty bioprocessing equipment will be integrated from many exhibiting partners including: Eppendorf, Getinge, Rotronic Instrument Corporation, STERIS Barrier Product Solutions, STERIS, Thermo Fisher Scientific, Carltex, BMT USA and TSI Inc.

“The pharmaceutical industry is under intense pressure to adapt production processes and facilities that keep up with the rapid pace of innovation.” said Jeff Serle, Senior Vice President, Germfree. “We’ve developed the Adaptive Bioproduction Suite to provide the next level of flexibility. It was also critical for our platform to be engineered as a self-contained, stand-alone facility that can be easily repurposed and relocated anywhere in the world.”

Germfree’s Adaptive Bioproduction Suites are optimal for a wide range of biopharmaceutical production applications including: monoclonal antibodies, therapeutic proteins, gene therapy, viral vector and live virus vaccines. Adaptive trailers offer flexible cleanroom space that is easily configured to required ISO grades as well as biological safety levels up to BSL-3. These capabilities help facilitate the rapid development and clinical trial manufacturing processes that are critical to product pipeline success.

“The Adaptive Trailers provide new options for fast and flexible cGMP/biocontainment production space that would be impractical in a brick and mortar building.” Says Carol Houts, Director of Quality, Germfree. “These units will also allow biotechnology companies to solve small scale processing challenges especially for precision medicine.” Germfree’s technology will be demonstrated, together with product innovations from participating partner vendors in booth 3961 at the Jacob Javits Center in New York City.

###

 

Germfree BioPharma Logo
Germfree designs and manufactures flexible bioproduction and R&D platforms. Our adaptive mobile suites and modular facilities provide advanced cGMP-compliant cleanrooms and biocontainment. We also integrate core equipment including our lines of interchangeable laminar flow hoods and containment equipment.

Germfree was established in 1962 to provide biosafety and aseptic control systems for institutions ranging from hospital pharmacies to high containment BSL-4 laboratories. We continue to expand and adapt our technologies. For the past 17 years, Germfree has manufactured mobile and modular BSL-3 labs to meet the rigorous demands of military and public health institutions globally, with facilities deployed to the harshest environments. This engineering experience makes us uniquely qualified to provide cleanroom platforms that offer quality, safety and durability that exceed traditional facilities. Our leading-edge fabrication technology, engineering teams and subject-matter experts are located at our 173,000 square foot (16,000 square meter) US manufacturing plant.
Booth #3961
 


For the past 38 years, INTERPHEX has been, and continues to be, the premier pharmaceutical, biotechnology, and device development and manufacturing event where you can “Experience Science through Commercialization.” Sponsored by the Parenteral Drug Association (PDA), the event is based in New York and brings over 11,500 global industry professionals and 625+ industry leading suppliers together to “Learn it, Experience it, Procure it” through a unique combination of no cost technical conference, exhibits, demonstrations, workshops, partnering opportunities and networking to leverage quality, efficiency and cost effectiveness in today’s ever-changing global market. INTERPHEX offers annual domestic and international industry events and educational opportunities around the world. For more information, please visit INTERPHEX.com.
 


With headquarters in New York, we are a subsidiary of Eppendorf AG (Hamburg, Germany) – manufacturer of laboratory instruments and consumables for the life sciences. You’ll see Eppendorf products used in all types of life science research and testing settings – from basic laboratory applications to highly specialized cell and molecular biology applications. They are highly regarded for their quality design and performance – beginning with extensive research and development, adding state-of-the-art technology and ending with strict quality-controlled manufacturing are what make our products stand out from the rest. It is what has made us a brand you have been able to rely on for over 70 years. For more information, please visit eppendorf.com
Booth #3639
 


Getinge Group is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. The aim is to be the most desired medtech company in the world. Getinge’s offering is mainly targeted at care providers, care givers and care receivers. The offering to hospitals is organized in three areas: Enable, Treat and Care. This allows Getinge to identify customer issues at an early stage, promote clinical and economic benefits and follow and support the customer decision process. Getinge’s unique offering mirrors the hospital’s organization and value chain, and the solutions are used before, during and after the patients’ hospital stay. For more information, please visit getinge.com
Booth #3133
 


The Rotronic Monitoring System (RMS) is the future of monitoring and it is available now. RMS is platform agnostic and makes it easy to access real-time monitoring data any time, from any place, on any device. The System is fully browser based and complies with all relevant regulations and guidelines. RMS is a modular system of hardware elements and web-based software. It provides maximum flexibility in installation and ensures readily available data. The data loggers record measurements from Rotronic and third-party sensors and transmit them to the secure database. It stores information and makes it available to users, regardless of whether they access the database via a PC, Mac, tablet or smartphone. RMS is perfect for both large monitoring systems and for simple, small applications. Rotronic makes the database available as a secure cloud account. Rotronic manufactures a full range of individual components and software for the monitoring system. We also offer professional advice, installation, commissioning and maintenance for the installed RMS. For more information, please visit rotronic.com.
Booth #1670
 


STERIS Barrier Product Solutions, formerly General Econopak, Inc., provides solutions in the areas of aseptic technique, sterilization, cleanliness, and protection of personnel and equipment for the pharmaceutical, biotechnology, and allied markets. Among the many products designed and manufactured by STERIS Barrier Product Solutions are sterilization wrapping products, equipment/machine covers, cleanroom wipers and supplies, protective apparel, and cleanroom apparel packs. We are proud of our ability to provide products of excellent quality, supported by exceptional Customer service and delivery. The STERIS Barrier Product Solutions, GEPCO and Econ-o-Pak names are widely recognized by our Customers throughout the world. For over 40 years, STERIS Barrier Product Solutions has earned a reputation for expertise in solving our Customers’ toughest challenges and for providing delivery precisely when needed. We have validated manufacturing processes, certified cleanroom production capabilities, and documented technical data for all of our standard and custom designed products. For more information, please visit sterisbps.com
Booth #1678
 


STERIS is a leading provider of infection prevention and procedural surgical products and services, focused primarily on healthcare, pharmaceutical, research and medical device Customers. Our mission is to provide a healthier today and a safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. While the corporation was founded as Innovative Medical Technologies in 1985 and renamed STERIS in 1987, our history dates back to 1894 with the founding of American Sterilizer Company, a long-time, global leading innovator of sterilization products. Today, through a series of strategic acquisitions and continual innovation of new products, STERIS holds one of the broadest portfolios of products in the industry. It stands at the forefront of efforts to prevent infection and contamination in healthcare, pharmaceutical and medical device environments. For more information, please visit steris.com.
Booth #3121
 


Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit thermofisher.com.
Booth #3544
 


Carltex Inc. is located in Nyack, NY with sales and support facilities. All sales are from the NY office. Now celebrating 19 years, Carltex supplies a wide variety of data acquisition, measurement & control, validation, and microscopy & imaging products. For More information, please visit carltex.com.
Booth #1967
 


BMT USA is a member of the MMM Group; one of the world’s leading suppliers of process equipment with subsidiaries in over 20 different countries and manufacturing facilities in the USA, Germany and the Czech Republic. Since the beginning in 1954, the group’s sterile products have been placed in Pharmaceutical, Laboratory and Healthcare facilities throughout the world. Special attention is given to quality, reliability, innovation, and efficiency of every unit. Constant review, customer input, and our commitment to improvement helps ensure our products meet the constantly changing requirements and needs of our customers. We understand the important role of our products to research and production facilities, and we strive to provide the most reliable, state-of-the-art equipment available. Customer service excellence is our philosophy and our commitment to your organization. We believe this is the best way to achieve your continued business and is the key to our success. For more information, please visit bmtus.com.
Booth #1742
 


TSI Inc. serves a global market by investigating, identifying and solving measurement problems. As an industry leader in the design and production of precision measurement instruments, TSI partners with research institutions and customers around the world to set the standard for measurements relating to aerosol science, air flow, chemical analysis, indoor air quality, fluid dynamics, biohazard detection, and even scrap metal sorting and plastics identification. With headquarters based in the U.S. and field offices throughout Europe and Asia, TSI has established a worldwide presence in the markets we serve. Every day, our dedicated employees turn research into reality. TSI has a worldwide presence with over 500 dedicated employees working in facilities in North America, Europe and Asia. Our corporate sales and service offices (St. Paul, Minnesota, USA; Aachen, Germany; High Wycombe, United Kingdom; Beijing, China; Shanghai, China; Singapore, and Bangalore, India) provide regional customer support. We also maintain a network of knowledgeable manufacturers’ representatives and distributors to provide local support worldwide. For more information, please visit TSI.com
Booth #1939

RALEIGH, NC, Updated: September 29th, 2015 — Duke Raleigh Hospital recently became the first healthcare facility to utilize a certified USP 797 mobile cleanroom to assure uninterrupted pharmacy services. The advanced pharmacy unit, created by Germfree Labs, allowed the hospital to maintain separate, on-site sterile drug compounding operations during a major renovation project.

May 20, 2014 — ‘New Facility to Detect and Respond to Outbreaks of Infectious Disease’
‘Advanced Disease Surveillance: Regional Lab Will Boost Global Biological Security’

For additional information about this news release please contact: Craig Landy: [email protected]
+1 386-265-4300 Direct: +1 312-238-9785 +1 386-316-2799

Organizations Participating In This Initiative

The BSL-3 lab was funded the government of Canada and is an initiative of The
Global Partnership Program:
Biological Security – Global Partnership Program (GPP) – Department Foreign Affairs, Trade and Development Canada: GPP “works to prevent terrorists and states of concern from acquiring or developing biological weapons and related materials, equipment, and technology.” Key roles of the program include working to: “Detect and report deliberately caused disease by strengthening regional and subregional disease surveillance and detection networks, supporting the gathering of epidemic intelligence, broadening international disease reporting networks…”

The facility will be operated by CARPHA:
The Caribbean Public Health Agency (CARPHA): CARPHA is the new single regional public health agency for the Caribbean. The BSL-3 Lab, the first of its kind in the region, will be run by CARPHA. Dr. C. James Hospedales is the Executive Director of the Agency.

The BSL-3 laboratory was manufactured and installed by Germfree:
Germfree Labs: Established in 1962, Germfree is the only company that designs, engineers and manufacturers all the critical primary and secondary bio-containment equipment for modular facilities. Germfree has extensive experience in delivering modular biological containment labs to the Americas, Europe, Asia and Africa.

This initiative will be run in cooperation with PAHO:
The Pan American Health Organization: PAHO is the Regional Office for the Americas of the World Health Organization (WHO)

Ministry of Health, Trinidad and Tobago: Dr. Fuad Khan is the Minister of Health.
High Commission of Canada to Trinidad and Tobago: His Excellency Gérard Latulippe is the High Commissioner.

Additional Remarks From Officials and Dignitaries
Involved with This Initiative

“In our modern age where global travel is routine and disease knows no boundaries a well-equipped safe and secure biological laboratory is an essential tool in the fight against infectious disease.”
— Gérard Latulippe, High Commissioner for Canada to Trinidad & Tobago

Remarks About Emerging Diseases:
As underscored by ongoing outbreaks of disease such as the Chikungunya here the Caribbean as well as Ebola in West Africa and the Middle East Respiratory Syndrome in the Middle East [MERS] isolated disease threat can very quickly become regional or global menace presenting serious threats to the health safety and security of the people of the world. Strengthening health security is a critical important complex issue that requires concerted efforts around the world and across many sectors. No country can insure it’s own health and security through national measures alone.
— Gérard Latulippe, High Commissioner for Canada to Trinidad & Tobago

“Currently there are several public health events of international concern reported elsewhere and in our region. Outbreaks of wild Polio in ten countries in Africa and Asia, MERS Coronavirus cases over the last two years effecting a few Middle Eastern countries and reported cases in the UK and the US, Chikungunya virus in the Caribbean, Ebola in the Western African countries, Rabies outbreaks in five countries in the Americas, Cholera in Haiti, the Dominican Republic and other countries in the region. Therefore having proper laboratory support and services in this regard would be very paramount.”
— Dr. Yitades Gebre, Advisor, Family Health and Disease Management, WHO / PAHO

Remarks About The Intersection Of Bioterrorism And Disease:
High Commissioner Latulippe explains the concept of the ‘health-security interface’, where shared surveillance infrastructure are complementary in global efforts to monitor and prevent both natural epidemics and deliberate biological threats.

“A strong global partnership is required at the ‘health-security interface’, that broad area that exists between natural and deliberate disease, where the interests and activities of two very different sectors intersect and align. Such multi-sectoral cooperation is rooted in the mutual recognition that though the motivations may be very different – combatting natural disease versus preventing or detecting deliberate biological attacks – the tools, infrastructure and capacities required to accomplish both health and security objectives is the same.”

“Sadly, we know that terrorist and other criminal groups remain committed to acquiring biological and other weapons or materials of mass destruction in order to launch devastating attacks. No country or region, irrespective of its size or location, is immune to these challenges.”
— Gérard Latulippe, High Commissioner for Canada to Trinidad & Tobago

Remarks About the Laboratory and Its Role in Global Public Health and Biosecurity:
“This a strategic public health resource for the Americas and for the world.”
— Dr. C. James Hospedales, Executive Director, Caribbean Public Health Agency (CARPHA)

“The laboratory known as a biological safety level 3 facility will strengthen CARPHA’s capacity to detect diagnose and respond to infectious disease outbreaks across the region, whether they be naturally occurring or deliberately caused.”
“It is set up to process and rapidly identify, in a safe and secure environment, samples suspected for a diverse range of diseases – including Yellow fever, West Nile virus, Rabies, Hantavirus, Anthrax, drug resistant MTB and emerging infectious diseases with epidemic potential. The facility also provides advanced primary and secondary containment systems required to handle other biological-risk agents and materials of unknown origin, including potential bioterrorism agents.”
— Gérard Latulippe, High Commissioner for Canada to Trinidad & Tobago

“This first class lab will enable us to be even better prepared for any emergencies that can be caused by pathogenic agents through early detection and enhanced response capabilities.”
— Dr. Fuad Khan, Minister of Health, Trinidad and Tobago

“Let me assure you that this facility – which was designed and manufactured by Germfree, a US company that has extensive experience providing similar bio-containment facilities around the world was built in strict accordance with international standards to ensure the safety and security of CARPHA personnel, the local population and the environment.”
— Gérard Latulippe, High Commissioner for Canada to Trinidad & Tobago

“When we were approached by Canada’s Global Partnership program we were excited to collaborate with their experts in bio-containment engineering and biosecurity to develop a BSL-3 Laboratory for CARPHA. We were challenged to be creative and innovative in our approach to this lab. Energy savings and sustainability were critical goals for this project. We had to rethink how a BSL-3 lab is built. Working with Canada’s biocontainment experts, we made every component energy efficient. Bioseals create a barrier for heat generating equipment. HVAC and containment controls sense and adjust for personnel occupancy and overall efficiency is also monitored remotely. We achieved a 41% reduction of energy consumption by implementing strategies that are unprecedented for a BSL-3 compliant laboratory”
— Jeff Serle, Germfree Labs, General Manager (U.S. Manufacturer of the Lab)

Remarks About the Global Role of Regional Labs:
Dr. Hospedales explains the precedent for regional labs playing a critical role in global public health:

“These Facilities here have discovered more than twenty viruses that were not known to science before. These are the labs that led the charge; we were the first region in the world to eliminate Measles in 1991. In 1992 and 1993 we had friends and colleagues from the CDC and Europe, France and England, coming to say ‘How did you do it?’ And that led to the Americas eliminating Measles.”
— Dr. C. James Hospedales, Executive Director, Caribbean Public Health Agency (CARPHA)

Media contact for this news release: Craig Landy: [email protected]
+1 386-265-4300 Direct: +1 312-238-9785 +1 386-316-2799

Full remarks from the laboratory handover event are available here:
https://www.youtube.com/user/CARPHACampus

NEWS RELEASE:
May 20, 2014 — ‘New Facility to Detect and Respond to Outbreaks of Infectious Disease’
‘Advanced Disease Surveillance: Regional Lab Will Boost Global Biological Security’

The Newest Strategy in Africa for Global Health Security
Critical Outpost Deployed to Front Lines of Emerging Diseases

ZARIA, NIGERIA; ORMOND BEACH, FL. –June 13th, 2010 – An unprecedented achievement within the complex arena of global health security will be unveiled in Zaria, Nigeria on June 14th. The new approach deploys high containment laboratories directly to the affected region. This provides researchers with all critical resources needed to work with highly pathogenic agents. Researchers on the ground can now provide an immediate, local response, thus containing an emerging threat before it spreads within the area of origin or to other areas of the world.

The facility, to be visited Monday by the U.S. CDC Director, the U.S. Ambassador to Nigeria, and key Nigerian leaders, allows researchers to safely work with dangerous pathogens such as MDR-TB (Multi-Drug Resistant Tuberculosis). For the first time, researchers in the region can work within a ‘BSL-3’ (Biological Safety Level-3) Lab to contain these highly infectious diseases. The lab protects the researchers while ensuring that a new deadly strain cannot escape from the facility and into the environment.

The new facility, funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) was manufactured in modules in Ormond Beach, Florida. The units were made for sustainable operability in the harshest of local conditions, ranging from unpredictable power to the severe sub-Saharan dust storms, known as ‘the Harmattan’.

“Should there be an outbreak like the one in South Africa, Nigeria now has the capability to control such an outbreak.” according to Dr. Alash’le Abimiku, the virologist at the Institute of Human Virology in Maryland that orchestrated the bi-national project. A key focus at the lab is the connection between HIV and MDR-TB. “One cannot deal with the isolation of a resistant pattern without a BSL-3 facility.” according to Dr. Abimiku. “This project is very significant for Sub-Saharan Africa that is totally devastated by HIV and AIDS.”

“Essentially what’s been provided here is a world class laboratory that’s supporting the people in the trenches fighting the disease.” says Stan Duarte, a bio-safety specialist at Morehouse School of Medicine, who provided on-site operational training for the project in Zaria.

“We built a very advanced high-containment facility in our factory in Florida, then disassembled, shipped and reassembled it in a remote region of Africa and set it up to begin handling high risk pathogens – and under some of the most adverse environmental conditions” says Keith Landy, President of Germfree, the manufacturer of the lab. “This kind of thing has never been done before.”

# # #

Additional Info/Press Release Backgrounder [Issued June 13th, 2010]

Alash’le Abimiku-Lorentzen, M.Sc. PhD; Exec. Dir. BSL-3 lab in Zaria, co.-P.I. IHV-Nigeria; Assistant Professor, Medicine, University of Maryland School of Medicine, Institute of Human Virology, Baltimore, MD. Born, Nigeria; According to The Institute of Human Virology, “It was Abimiku, in fact, who first isolated, then scientifically analyzed and characterized the HIV strain most prevalent in Nigeria and the rest of West Africa and now recognized as the second leading cause of HIV infection worldwide.”

Additional quotes from Dr. Abimiku related to the Press Release:

“Now that they have this lab, the Nigerian Government’s priority is an optimal TB national survey because for the first time we have the capacity to actually culture it and within a very controlled area. Should there be an outbreak like the one in South Africa, Nigeria now has the capability to control such an outbreak. We didn’t have that capability before in terms of looking at the isolates – looking at the kind of resistant path and then knowing how to appropriately treat patients.”

“We know that in developing countries one of the biggest challenges for HIV infected individuals is opportunistic infections – that’s really what kills them — and the biggest killer among those secondary infections of HIV infected individuals is TB. The treatment is pretty complex and must be undergone for an extended duration. It is that much worse on individuals already compromised as a result of HIV infection or with TB that’s resistant to multiple drugs. This project is very significant for Sub-Saharan Africa that is totally devastated by HIV and AIDS.”

“As far as we know and as far as international safety guidelines go, the ability to look at the infecting TB Mycobacterium and look at the pattern of drug resistance that is being developed is totally dependent on having a BSL-3 facility. In an area where drug resistance is a potential and is a problem – one cannot deal with the isolation of a resistant pattern without a BSL-3 facility. Without that I don’t think the Nigerian government would be able to rule out second line TB drugs or even be able to manage patients that are infected with multi-resistant TB.”

Thomas R. Frieden, MD, MPH: According to the CDC website he “became Director of the Centers for Disease Control and Prevention (CDC) and Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR) in June 2009. Dr. Frieden has worked to control both communicable and non-communicable diseases in the United States and around the world. From 1992-1996, he led New York City’s program that rapidly controlled tuberculosis, including reducing cases of multidrug-resistant tuberculosis by 80 percent. He then worked in India for five years where he assisted with national tuberculosis control efforts. The program in India has treated more than 10 million patients and has saved more than one million lives.” SOURCE: www.cdc.gov/about/leadership/leaders/Frieden.htm

Recent Quotes from the CDC Director Frieden, relevant to content of the Press Release, particularly‘global health security’ – CSIS, Washington, DC, May 5th, 2010:

“Our lives depend on good global surveillance. And that’s going to require strengthening ministries of health in public health emergency response and also in the establishment and maintenance of surveillance and strategic information systems, critically important.” [Transcribed from Video – link below – quote at minutes: seconds:

“Clearly we are all connected by the air we breathe and there is a lot that we need to do together. Weak surveillance in any country is a risk to all of us. We need coordinated systems to detect and respond to infectious diseases and we need quicker identification.”

“Hand in hand with epidemiological capacity, is strengthening global laboratory capacity. This is one of the most concrete useful aspects of health system strengthening…having competent laboratories that can diagnose cases at the national, referral and clinical levels is critically important.”

“The first component is political commitment. There is a need to link public health action and policy change to build public health capacity in developing countries.”

Quote SOURCE: http://csis.org/event/cdcs-global-health-agenda-partnering-rapid-progress-global-public-health Speaking at the Center for Strategic and International Studies ‘CDC’s Global Health Agenda: Partnering for Rapid Progress in Global Public Health’

CSIS- Center for Strategic and International Studies – Global Health Policy Center: “Bridging the foreign policy and public health communities by creating a strategy for U.S. engagement on global health.”
http://csis.org/category/topics/global-health

PEPFAR – The U.S. President’s Emergency Plan for AIDS Relief: According to organization: “PEPFAR holds a place in history as the largest effort by any nation to combat a single disease.” Focus on Local Sustainability: “Sustainable programs must be country-owned and country-driven. Given that the AIDS epidemic represents a shared global burden among nations, the next phase of PEPFAR represents an opportunity for the United States to support shared responsibility with partner countries. To seize this opportunity, PEPFAR is supporting countries in taking leadership of the responses to their epidemics. In addition, to support an expanded collective impact at the country level, PEPFAR is increasing collaboration with multilateral organizations. “ SOURCE: www.pepfar.gov

Institute for Human Virology, Baltimore, MD: According to the organization: “The Institute of Human Virology is the first center in the United States — perhaps the world — to combine the disciplines of basic research, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders – most notably the HIV virus that causes AIDS.” Source:http://www.ihv.org/about/index.html

HIV, TB and Drug-resistant TB: According to WHO (The World Health Organization): “HIV and TB form a lethal combination, each speeding the other’s progress. HIV weakens the immune system. Someone who is HIV-positive and infected with TB bacilli is many times more likely to become sick with TB than someone infected with TB bacilli who is HIV-negative. TB is a leading cause of death among people who are HIV-positive. In Africa, HIV is the single most important factor contributing to the increase in the incidence of TB since 1990.”

“Until 50 years ago, there were no medicines to cure TB. Now, strains that are resistant to a single drug have been documented in every country surveyed; what is more, strains of TB resistant to all major anti-TB drugs have emerged. Drug-resistant TB is caused by inconsistent or partial treatment, when patients do not take all their medicines regularly for the required period because they start to feel better, because doctors and health workers prescribe the wrong treatment regimens, or because the drug supply is unreliable. A particularly dangerous form of drug-resistant TB is multidrug-resistant TB (MDR-TB), which is defined as the disease caused by TB bacilli resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs.” SOURCE: http://www.who.int/mediacentre/factsheets/fs104/en/

FOR DISTRIBUTION TO NEWSWIRE SUBSCRIBERS ONLY

Media Contacts: [email protected]

Jeanne Stalzer – (+1) 386-265-4360; Craig Landy – (+1) 386-316-2799

ADDITIONAL EXPERT QUOTES

Monica Heyl

“In that I am currently attending the 5th Annual National Bio-Threat Conference (27-29 March 2012, Denver, Colorado); it is quite timely to hear that Germfree Laboratories, Inc. has worked with the Mexican Government on the development of their mobile public health laboratory. Global collaboration is essential in strengthening the security of nations by preventing and reducing biological threat(s), both deliberate and naturally occurring. In that Mexico and the US share almost 2000 miles of border, we are deeply connected. Providing Mexico with this public health capability contributes to our global capacity in health, disease surveillance, early warning, response, recovery and mitigation by providing one more tool in protecting the health of our world.”

Monica Heyl: Recognized International Mobile Laboratory Expert. Served as the Leader of the US Army’s Mobile Laboratory & Kits (ML&K) Team and the Advanced CBRNE Training Team. Currently: Monica Heyl & Associates

Olga Piña Gutiérrez

“This mobile laboratory is a significant advancement for public health, providing early surveillance of potential outbreaks.”

Quim. Olga Piña Gutiérrez: Director, Tabasco State Public Health Laboratory

Dr. Celia Alpuche Aranda

[Translated from Spanish text]

“This unit provides mobile epidemiological surveillance for our state public health labs, now allowing them to access difficult areas when there is a disaster or outbreak. The lab is a new tool to optimize sample collection and on-site management, and in many cases a diagnosis, right on the spot where the problem is occurring.”

“This laboratory is the first in Mexico and Latin America that provides this level of biosafety and biosecurity in a mobile unit.”

“This lab allows us to work in the flood zones to more rapidly assess the situation. It gives us the ability to diagnose diseases such as Cholera, Enterobacteriaceae, influenza, dengue, Leptospira, Rickettsia and Hepatitis A.”

“Producing more timely and better quality laboratory information for epidemiological intelligence gives us a much better response for controlling these problems.”

Dr. Celia Alpuche Aranda: Director, InDRE (Instituto de Diagnóstico y Referencia Epidemiológicos). InDRE is the federal agency in Mexico that is the counterpart to the CDC (US Centers for Disease Control & Prevention).

Dr. Steve Jones

“This new mobile laboratory represents a significant improvement to the regional contribution to global health security. The lab enables the community to quickly and effectively respond to large outbreaks of infectious disease in a manner that will greatly reduce their impact both locally and internationally. The region has to contend annually with very severe weather conditions that exacerbate natural disease outbreaks making reliance on fixed laboratories unfeasible. This lab will put cutting-edge diagnostic capability directly into the outbreak zone. The turn-around time for critical results will be slashed and the public health system will have reliable, high quality data which is essential for critical decisions in a public health emergency.”

Dr. Steven Jones: Former Director, Counter Bio-Terrorism Operations for the Public Health Agency of Canada at the Vancouver 2010 Olympics and G8/G20 Summits. Currently: President, Cognoveritas Consulting

Keith Landy

“This mobile bio-containment lab provides a completely unique approach to early, on-site detection of potential epidemics. When there’s an outbreak in a remote area it is critical to quickly identify the pathogen so that effective public health measures can be implemented.

There are major advantages to deploying the lab directly to the affected region versus transporting hazardous samples over long distances to a fixed-site facility. Our lab allows personnel to respond to an outbreak of disease directly at the source saving crucial time.

Accelerated, on-site risk assessment is an innovative modality that enables public health and government officials to more effectively manage a natural disease outbreak.”

Keith Landy: President, Germfree Labs

MORE ABOUT GERMFREE

Germfree is a manufacturer based in Ormond Beach, Florida, US, that provides bio-containment solutions in Europe, Africa, Asia-Pacific Rim and the Americas. Germfree, established in 1962, has mobile and modular Labs in service worldwide for a range of public health, research and emergency preparedness missions. The company’s mobile units are also deployed for high profile events such as the Olympics and G8/G20 summits.

Sustainable Labs – Matching Local Resources: Germfree manufactures advanced bio-containment laboratories that are designed to meet the requirements of regions with limited utilities and infrastructure or severe environments.

Global Health Partnerships: Germfree’s also develops technology in cooperation with global health partnerships. These include: The Global Laboratory Initiative Group/Stop TB Partnership, WHO (World Health Organization) and the CDC (US Centers for Disease Control and Prevention).

Germfree Logos available for media use.

May 20, 2014 — ‘New Facility to Detect and Respond to Outbreaks of Infectious Disease’
‘Advanced Disease Surveillance: Regional Lab Will Boost Global Biological Security’
For additional information about this news release please contact: Craig Landy: [email protected]
+1 386-265-4300 Direct: +1 312-238-9785 +1 386-316-2799

Organizations Participating In This Initiative
The BSL-3 lab was funded the government of Canada and is an initiative of The
Global Partnership Program:
Biological Security – Global Partnership Program (GPP) – Department Foreign Affairs, Trade and Development Canada: GPP “works to prevent terrorists and states of concern from acquiring or developing biological weapons and related materials, equipment, and technology.” Key roles of the program include working to: “Detect and report deliberately caused disease by strengthening regional and subregional disease surveillance and detection networks, supporting the gathering of epidemic intelligence, broadening international disease reporting networks…”

The facility will be operated by CARPHA:
The Caribbean Public Health Agency (CARPHA): CARPHA is the new single regional public health agency for the Caribbean. The BSL-3 Lab, the first of its kind in the region, will be run by CARPHA. Dr. C. James Hospedales is the Executive Director of the Agency.

The BSL-3 laboratory was manufactured and installed by Germfree:
Germfree Labs: Established in 1962, Germfree is the only company that designs, engineers and manufacturers all the critical primary and secondary bio-containment equipment for modular facilities. Germfree has extensive experience in delivering modular biological containment labs to the Americas, Europe, Asia and Africa.

This initiative will be run in cooperation with PAHO:
The Pan American Health Organization: PAHO is the Regional Office for the Americas of the World Health Organization (WHO)

Ministry of Health, Trinidad and Tobago: Dr. Fuad Khan is the Minister of Health.

High Commission of Canada to Trinidad and Tobago: His Excellency Gérard Latulippe is the High Commissioner.

Additional Remarks From Officials and Dignitaries Involved with This Initiative

“In our modern age where global travel is routine and disease knows no boundaries a well-equipped safe and secure biological laboratory is an essential tool in the fight against infectious disease.”
— Gérard Latulippe, High Commissioner for Canada to Trinidad & Tobago

Remarks About Emerging Diseases:
As underscored by ongoing outbreaks of disease such as the Chikungunya here the Caribbean as well as Ebola in West Africa and the Middle East Respiratory Syndrome in the Middle East [MERS] isolated disease threat can very quickly become regional or global menace presenting serious threats to the health safety and security of the people of the world. Strengthening health security is a critical important complex issue that requires concerted efforts around the world and across many sectors. No country can insure it’s own health and security through national measures alone.
— Gérard Latulippe, High Commissioner for Canada to Trinidad & Tobago

“Currently there are several public health events of international concern reported elsewhere and in our region. Outbreaks of wild Polio in ten countries in Africa and Asia, MERS Coronavirus cases over the last two years effecting a few Middle Eastern countries and reported cases in the UK and the US, Chikungunya virus in the Caribbean, Ebola in the Western African countries, Rabies outbreaks in five countries in the Americas, Cholera in Haiti, the Dominican Republic and other countries in the region. Therefore having proper laboratory support and services in this regard would be very paramount.”
— Dr. Yitades Gebre, Advisor, Family Health and Disease Management, WHO / PAHO

Remarks About The Intersection Of Bioterrorism And Disease:
High Commissioner Latulippe explains the concept of the ‘health-security interface’, where shared surveillance infrastructure are complementary in global efforts to monitor and prevent both natural epidemics and deliberate biological threats.

“A strong global partnership is required at the ‘health-security interface’, that broad area that exists between natural and deliberate disease, where the interests and activities of two very different sectors intersect and align. Such multi-sectoral cooperation is rooted in the mutual recognition that though the motivations may be very different – combatting natural disease versus preventing or detecting deliberate biological attacks – the tools, infrastructure and capacities required to accomplish both health and security objectives is the same.”

“Sadly, we know that terrorist and other criminal groups remain committed to acquiring biological and other weapons or materials of mass destruction in order to launch devastating attacks. No country or region, irrespective of its size or location, is immune to these challenges.”
— Gérard Latulippe, High Commissioner for Canada to Trinidad & Tobago

Remarks About the Laboratory and Its Role in Global Public Health and Biosecurity:
“This a strategic public health resource for the Americas and for the world.”
— Dr. C. James Hospedales, Executive Director, Caribbean Public Health Agency (CARPHA)

“The laboratory known as a biological safety level 3 facility will strengthen CARPHA’s capacity to detect diagnose and respond to infectious disease outbreaks across the region, whether they be naturally occurring or deliberately caused.”
“It is set up to process and rapidly identify, in a safe and secure environment, samples suspected for a diverse range of diseases – including Yellow fever, West Nile virus, Rabies, Hantavirus, Anthrax, drug resistant MTB and emerging infectious diseases with epidemic potential. The facility also provides advanced primary and secondary containment systems required to handle other biological-risk agents and materials of unknown origin, including potential bioterrorism agents.”
— Gérard Latulippe, High Commissioner for Canada to Trinidad & Tobago

“This first class lab will enable us to be even better prepared for any emergencies that can be caused by pathogenic agents through early detection and enhanced response capabilities.”
— Dr. Fuad Khan, Minister of Health, Trinidad and Tobago

“Let me assure you that this facility – which was designed and manufactured by Germfree, a US company that has extensive experience providing similar bio-containment facilities around the world was built in strict accordance with international standards to ensure the safety and security of CARPHA personnel, the local population and the environment.”
— Gérard Latulippe, High Commissioner for Canada to Trinidad & Tobago

“When we were approached by Canada’s Global Partnership program we were excited to collaborate with their experts in bio-containment engineering and biosecurity to develop a BSL-3 Laboratory for CARPHA. We were challenged to be creative and innovative in our approach to this lab. Energy savings and sustainability were critical goals for this project. We had to rethink how a BSL-3 lab is built. Working with Canada’s biocontainment experts, we made every component energy efficient. Bioseals create a barrier for heat generating equipment. HVAC and containment controls sense and adjust for personnel occupancy and overall efficiency is also monitored remotely. We achieved a 41% reduction of energy consumption by implementing strategies that are unprecedented for a BSL-3 compliant laboratory”
— Jeff Serle, Germfree Labs, General Manager (U.S. Manufacturer of the Lab)

Remarks About the Global Role of Regional Labs:
Dr. Hospedales explains the precedent for regional labs playing a critical role in global public health:

“These Facilities here have discovered more than twenty viruses that were not known to science before. These are the labs that led the charge; we were the first region in the world to eliminate Measles in 1991. In 1992 and 1993 we had friends and colleagues from the CDC and Europe, France and England, coming to say ‘How did you do it?’ And that led to the Americas eliminating Measles.”
— Dr. C. James Hospedales, Executive Director, Caribbean Public Health Agency (CARPHA)

Media contact for this news release: Craig Landy: [email protected]
+1 386-265-4300 Direct: +1 312-238-9785 +1 386-316-2799

Full remarks from the laboratory handover event are available here:
https://www.youtube.com/user/CARPHACampus

NEWS RELEASE:
May 20, 2014 — ‘New Facility to Detect and Respond to Outbreaks of Infectious Disease’
‘Advanced Disease Surveillance: Regional Lab Will Boost Global Biological Security’